Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    TopAbstracts in Lung Cancer 10/28/2009 - (DGNews)
    TopAbstracts in Lung Cancer 10/14/2009 - (DGNews)
    CD4 Cell Count Key to Predicting Risk of Cancers in Patients With HIV - (DGNews)
    Combination of PET/CT Scans Can Expedite Diagnosis of Lung Cancer In a Fast-Track Setting - (DGNews)
    Gefitinib Shows Significant Survival Benefits Over Carboplatin/Paclitaxel in First-Line Treatment of NSCLC: Presented at ECCO-ESMO - (DGDispatch)

    News archive

     Recent webcasts/CME - Lung Cancer

    Webcasts/CME archive

     Recent cases - Lung Cancer
      An Unusual Case of Finger Swelling: A Case Report
      Paraneoplastic Nephrotic Syndrome in Patients with Lung Cancer
      Gefitinib for Non-Small Cell Lung Cancer Patients with Liver Cirrhosis
      Occult Very Small Lung Carcinoma with a Solitary Brain Metastasis That is Clinically Diagnosed as Cavernous Hemangioma: A Case Report
      Pleuropulmonary Blastoma Type I Following Resection of Incidentally Found Congenital Lobar Emphysema

      Cases archive
        




      my personal edition > lung cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      ZD1839 (Iressa) With Standard Chemotherapy Does Not Improve Outcome in Advanced NSCLC: Presented at ESMO

      By Adrian Burton

      NICE, FRANCE -- October 23, 2002 -- Adding ZD 1839 (Iressa) to standard chemotherapy regimens offers no clinical benefit in patients with advanced non-small cell lung cancer (NSCLC), according to the combined results of two randomized, double-blind, placebo-controlled, multicentre trials reported here October 21st at the 27th Congress of the European Society for Medical Oncology.

      Earlier studies (the IDEAL trials) had shown that ZD 1839 (an inhibitor of epidermal growth factor receptor tyrosine kinase) has an extremely promising activity profile when used as monotherapy.

      "It was clear to all of us in the field that we had reached a plateau in the therapy of metastatic lung cancer," said Dr. David Johnson, Deputy Director of the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States. "When four of the most popular chemotherapy regimens in the world were recently compared, none emerged as superior. We thought that adding a third drug [Iressa] to some of these doublets might be a useful strategy. We hoped we might see an improvement."

      The 2130 patients enrolled in the trials had grade ¾ NSCLC, were chemotherapy-naive, and had a European Cooperative Oncology Group performance status of 0-2. Median patient age was 61 years in the INTACT I trial and 62 years in INTACT II.

      Patients in Europe were randomly assigned to one of three treatment groups: (1) six cycles of chemotherapy (CT) with gemcitabine 1250 mg/m² on days 1 and 8 +cisplatin 80 mg/m² on day 1 + a placebo, (2) six cycles of CT + ZD 1839 250 mg/d, or (3) six cycles of CT + ZD 1839 500 mg/d. North American patients received one of the following regimens: (1) carboplatin area under the curve 6 + paclitaxel 250 mg/m² + placebo every 3 weeks, (2) the same + 250 mg/d ZD1839, or (3) the same + 500 mg/d ZD1839. All treatment groups were well balanced with regard to disease stage and demography.

      The primary end point was overall survival. Secondary end points included progression-free survival, time to worsening of symptoms, quality of life, and safety.

      Toxicity profiles of the ZD1839 arms were acceptable, although some cases of dose-dependent diarrhoea and skin rash were observed. No significant differences were seen with respect to overall survival -- which was approximately 9 months -- on any of the regimens. There were no differences in progression-free survival or time to worsening of symptoms. Comparative hazard ratios were also very similar for all treatments (between 9.0 and 1.0).

      "The bottom line is that there is no difference in outcome. Survival in the three arms, though numerically different, is statistically identical," explained Dr. Johnson. "Of course we are disappointed about the way these results turned out. We are now in the process of trying to find out what happened."

      Some data presented at the meeting suggest that the triplet may have some effect in the subset of adenocarcinoma patients.

      Though disappointing, there is more research to be done. "Sequential use of these agents rather than concomitant use might be a superior strategy," concluded Dr. Johnson. "The IDEAL data would seem to suggest that this might be the case."



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send